Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | Director · President and CEO | January 08, 2019 | January 10, 2019 |
| GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635 | Director | July 01, 2021 | July 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date January 08, 2019 · Filed January 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,204,966 |
Reported balance
After 2019-01-08 transaction · row 1
1 source rowRow 1 · 2019-01-08 · Sale · Disposed 12,000 · Balance 1,204,966 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F2: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.83. The price reported above reflected the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended.
F2: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.83. The price reported above reflected the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
GENOCEA BIOSCIENCES, INC.
Report date July 01, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.33 · Expires 2031-07-01 | Direct | 15,000 |
Reported balance
After 2021-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-01 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the options are scheduled to vest on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the options are scheduled to vest on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2021 Filed Jul 2, 2021 11:50 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001457612-21-000078 · wf-form4_162524102805109.xml · derivative · entry 1 Bosley Katrine · CIK 0001592469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: 100% of the options are scheduled to vest on the first anniversary of the grant date. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 16:08 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0001457612-20-000099 · wf-form4_159259728752944.xml · derivative · entry 1 Bosley Katrine · CIK 0001592469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| July 18, 2019 Filed Jul 19, 2019 16:05 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 5,625 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001457612-19-000110 · wf-form4_156356669720049.xml · derivative · entry 1 Bosley Katrine · CIK 0001592469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 5,625 shares Expires 2029-07-18 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 16:11 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 12,000 | $25.27 | $303,240.00 |
DisclosureSEC source: 0001179110-19-000653 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,204,966 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.83. The price reported above reflected the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 16:02 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 100 | $32.39 | $3,239.00 |
DisclosureSEC source: 0001179110-18-013511 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,216,966 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 16:02 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 11,900 | $31.92 | $379,848.00 |
DisclosureSEC source: 0001179110-18-013511 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,217,066 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $31.36 to $32.28. The price reported above reflected the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 17:42 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 8,600 | $27.21 | $234,006.00 |
DisclosureSEC source: 0001179110-18-012584 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,228,966 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F3 · price: This transaction was executed in multiple trades at prices ranging from $26.57 to $27.52. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 17:42 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 3,400 | $26.03 | $88,502.00 |
DisclosureSEC source: 0001179110-18-012584 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,237,566 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.49 to $26.44. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 16:03 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 5,766 | $31.44 | $181,283.04 |
DisclosureSEC source: 0001179110-18-011999 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,240,966 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F3 · price: This transaction was executed in multiple trades at prices ranging from $31.20 to $31.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 16:03 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 6,234 | $30.64 | $191,009.76 |
DisclosureSEC source: 0001179110-18-011999 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,246,732 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.20 to $31.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 16:02 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,213 | $33.07 | $40,113.91 |
DisclosureSEC source: 0001179110-18-011143 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,252,966 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F3 · price: This transaction was executed in multiple trades at prices ranging from $32.79 to $33.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 16:02 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 10,787 | $32.27 | $348,096.49 |
DisclosureSEC source: 0001179110-18-011143 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,254,179 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $31.79 to $32.78. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 16:16 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 5,433 | $30.43 | $165,326.19 |
DisclosureSEC source: 0001179110-18-010766 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,264,966 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F3 · price: This transaction was executed in multiple trades at prices ranging from $30.32 to $30.53. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 16:16 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 6,567 | $29.95 | $196,681.65 |
DisclosureSEC source: 0001179110-18-010766 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,270,399 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $29.32 to $30.31. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 16:01 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 2,100 | $30.12 | $63,252.00 |
DisclosureSEC source: 0001179110-18-010246 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,276,966 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F3 · price: This transaction was executed in multiple trades at prices ranging from $29.92 to $30.38. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 16:01 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 6,233 | $29.36 | $183,000.88 |
DisclosureSEC source: 0001179110-18-010246 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279,066 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.92 to $29.89. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 16:00 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 5,333 | $36.46 | $194,441.18 |
DisclosureSEC source: 0001179110-18-009472 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,285,299 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F3 · price: This transaction was executed in multiple trades at prices ranging from $36.32 to $36.64. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 16:00 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 3,000 | $36.00 | $108,000.00 |
DisclosureSEC source: 0001179110-18-009472 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,290,632 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.31 to $36.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:07 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001457612-18-000068 · wf-form4_152997163308505.xml · derivative · entry 1 Bosley Katrine · CIK 0001592469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the grant date. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 16:06 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 300 | $39.96 | $11,988.00 |
DisclosureSEC source: 0001179110-18-008050 · edgar.xml · nonDerivative · entry 4 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,293,632 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F5 · price: This transaction was executed in multiple trades at prices ranging from $39.785 to $40.12. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 16:06 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 800 | $39.15 | $31,320.00 |
DisclosureSEC source: 0001179110-18-008050 · edgar.xml · nonDerivative · entry 3 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,293,932 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F4 · price: This transaction was executed in multiple trades at prices ranging from $38.76 to $39.54. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 16:06 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,019 | $37.81 | $38,528.39 |
DisclosureSEC source: 0001179110-18-008050 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,294,732 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F3 · price: This transaction was executed in multiple trades at prices ranging from $37.67 to $38.15. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 16:06 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 6,214 | $37.18 | $231,036.52 |
DisclosureSEC source: 0001179110-18-008050 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,295,751 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $36.67 to $37.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2018 Filed May 3, 2018 17:31 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 8,333 | $31.95 | $266,239.35 |
DisclosureSEC source: 0001179110-18-006176 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301,965 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $31.50 to $32.49. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 16:05 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 3,500 | $32.61 | $114,135.00 |
DisclosureSEC source: 0001179110-18-005385 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,310,298 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $32.35 to $33.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 16:05 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 4,833 | $31.83 | $153,834.39 |
DisclosureSEC source: 0001179110-18-005385 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,313,798 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $31.35 to $32.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 08:45 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 9,134 | $45.00 | $411,030.00 |
DisclosureSEC source: 0001179110-18-004109 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,318,631 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.00 to $45.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 16:52 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,800 | $36.41 | $65,538.00 |
DisclosureSEC source: 0001179110-18-003455 · edgar.xml · nonDerivative · entry 3 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,327,765 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $36.21 to $36.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 16:52 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 4,800 | $35.87 | $172,176.00 |
DisclosureSEC source: 0001179110-18-003455 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,329,565 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $35.21 to $36.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 16:52 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,733 | $34.61 | $59,979.13 |
DisclosureSEC source: 0001179110-18-003455 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,334,365 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $34.19 to $35.13. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 17:25 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $36.67 | $0.00 |
DisclosureSEC source: 0001179110-18-001909 · edgar.xml · derivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2028-02-06 F1 · derivative.exercise_date: This option was granted on February 7, 2018 and is scheduled to vest over four years in equal monthly installments beginning on February 7, 2018 through February 7, 2022. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 18:05 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 700 | $37.60 | $26,322.10 |
DisclosureSEC source: 0001179110-18-001570 · edgar.xml · nonDerivative · entry 3 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,336,098 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $37.32 to $37.9. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 18:05 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 2,100 | $36.71 | $77,097.30 |
DisclosureSEC source: 0001179110-18-001570 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,336,798 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $36.35 to $37.29. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 18:05 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 5,533 | $35.79 | $198,031.60 |
DisclosureSEC source: 0001179110-18-001570 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,338,898 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.34 to $36.31. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 30, 2018 Filed Jan 31, 2018 16:18 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 10,000 | $40.05 | $400,520.00 |
DisclosureSEC source: 0001179110-18-001288 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,344,431 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $40 to $40.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 16:18 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 10,000 | $37.53 | $375,340.00 |
DisclosureSEC source: 0001179110-18-001288 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354,431 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.5 to $37.63. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 16:11 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 3,338 | $35.28 | $117,764.64 |
DisclosureSEC source: 0001179110-18-001072 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,364,431 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.21 to $35.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 16:09 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 6,662 | $35.04 | $233,416.49 |
DisclosureSEC source: 0001179110-18-000486 · edgar.xml · nonDerivative · entry 5 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,367,769 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F6 · price: This transaction was executed in multiple trades at prices ranging from $35 to $35.7. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:09 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 3,937 | $34.23 | $134,743.83 |
DisclosureSEC source: 0001179110-18-000486 · edgar.xml · nonDerivative · entry 4 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374,431 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F5 · price: This transaction was executed in multiple trades at prices ranging from $33.89 to $34.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:09 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 2,193 | $33.63 | $73,759.36 |
DisclosureSEC source: 0001179110-18-000486 · edgar.xml · nonDerivative · entry 3 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,378,368 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $32.89 to $33.87. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:09 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,703 | $32.01 | $54,509.62 |
DisclosureSEC source: 0001179110-18-000486 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,380,561 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $31.79 to $32.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:09 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 500 | $31.25 | $15,624.00 |
DisclosureSEC source: 0001179110-18-000486 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,382,264 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.75 to $31.71. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 06:08 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 5,133 | $29.88 | $153,348.38 |
DisclosureSEC source: 0001179110-17-014870 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,382,764 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $29.56 to $30.27. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 06:08 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 3,200 | $29.12 | $93,174.08 |
DisclosureSEC source: 0001179110-17-014870 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,387,897 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.54 to $29.47. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 16:48 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 300 | $25.05 | $7,514.10 |
DisclosureSEC source: 0001179110-17-013743 · edgar.xml · nonDerivative · entry 3 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,391,097 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $24.99 to $25.15. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 16:48 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,925 | $24.25 | $46,679.33 |
DisclosureSEC source: 0001179110-17-013743 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,391,397 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.99 to $24.64. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 16:48 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 6,108 | $23.37 | $142,772.67 |
DisclosureSEC source: 0001179110-17-013743 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,393,322 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.88 to $23.85. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 200 | $25.33 | $5,066.00 |
DisclosureSEC source: 0001179110-17-013103 · edgar.xml · nonDerivative · entry 2 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,399,430 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $25.32 to $25.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 8,133 | $24.77 | $201,459.29 |
DisclosureSEC source: 0001179110-17-013103 · edgar.xml · nonDerivative · entry 1 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,399,630 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.2 to $25.17. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 17:05 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 6,666 | $20.20 | $134,681.20 |
DisclosureSEC source: 0001179110-17-012109 · edgar.xml · nonDerivative · entry 3 Bosley Katrine · CIK 0001592469 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,407,763 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.85. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.